Semaglutide: Uses, Benefits, Dosage and Safety

Semaglutide is a once-weekly injection sold as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for weight management. It is one molecule under three names at different doses, and it is the best evidenced weight loss medicine most people will ever be offered.

It copies GLP-1, a hormone the gut releases after a meal to tell the brain that enough has arrived. The natural version survives about two minutes in the blood. Semaglutide survives about a week.

The reason it reset the field is not only the roughly 15% average weight loss. It is that a separate trial in people who already had heart disease found around 20% fewer heart attacks, strokes and cardiovascular deaths. That result moved it from a medicine that changes a number on a scale to one that changes what happens to people.

What is semaglutide?#

Semaglutide is a synthetic peptide closely modelled on human GLP-1, with three modifications that stop the body clearing it within minutes. It is given as a subcutaneous injection once a week, or as a daily tablet for diabetes.

If the underlying vocabulary is unfamiliar, what peptides actually are covers it.

Where it comes from#

Human GLP-1 is broken down almost immediately by an enzyme called DPP-4. Semaglutide changes one amino acid at the site that enzyme attacks, substitutes another, and attaches a fatty acid chain that binds it to albumin in the blood. The first two changes stop it being destroyed; the third stops it being filtered out by the kidneys.

Those three edits are the whole reason a weekly injection is possible. The molecule does what the hormone does; it simply refuses to leave.

Novo Nordisk brought it to market for type 2 diabetes in 2017 and for weight management in 2021.

Proposed mechanisms of action#

One receptor, three effects that a person actually notices.

• Appetite signalling in the brain. Semaglutide acts directly on the appetite centres of the hypothalamus and brainstem. This is the part users describe as the food noise going quiet.
• Slower stomach emptying. Food stays in the stomach longer, so fullness arrives sooner and lasts.
• Glucose-dependent insulin release. Insulin is released in response to a meal rather than continuously, which lowers blood sugar without the hypoglycaemia risk that older diabetes drugs carry.

The honest framing is that none of this burns fat or speeds up metabolism. It makes eating less feel unremarkable instead of like a daily argument.

What semaglutide is claimed to do#

Substantial weight loss#

The claim is that a person loses around a seventh of their body weight and stops fighting themselves to do it.

GLP-1 receptor agonism reduces appetite signalling centrally and slows gastric emptying, so both the wanting and the physical capacity move in the same direction.

In practice that describes finishing a plate that would previously have been the first of two, and not thinking about the next meal until it is due. People describe it as the volume being turned down rather than as discipline arriving.

This was measured in the STEP programme: adults on the weight management dose lost roughly 15% of body weight over 68 weeks, against about 2.4% on placebo, in large randomised placebo-controlled trials.

Fewer heart attacks and strokes#

The claim is the strongest one any compound on this site can make, which is that taking it changes whether something happens to you rather than changing a measurement.

The mechanism is not fully settled. Weight loss, lower blood pressure, improved lipids and a direct anti-inflammatory effect on blood vessels have all been proposed, and the effect appeared larger than the weight loss alone would predict.

What that would look like to a person is the difference between an event and no event. Not a better number at a review appointment, but an ambulance that is not called.

This was measured in SELECT, in over 17,000 people with existing cardiovascular disease and overweight or obesity but without diabetes, and reported roughly a 20% reduction in major adverse cardiovascular events.

Better blood sugar control#

The claim is reliable reduction in HbA1c, and this is the oldest and least contested of the three.

Glucose-dependent insulin release plus reduced glucagon output from the liver lowers both post-meal spikes and fasting levels.

Put another way, the pancreas responds when it should and the liver stops volunteering sugar between meals.

This has been measured across the SUSTAIN programme and in routine prescribing since 2017, which is now approaching a decade of accumulated safety and efficacy data.

Quieter thoughts about food#

The claim is the one people report most and trials measure least: the constant background negotiation about eating stops.

The mechanism is central appetite signalling rather than anything in the stomach, which is why it appears before any weight has moved.

Whether that matters to you depends on whether food has been occupying attention. For people who describe it that way, this is often the effect that matters more than the weight, and it is the reason some stay on the drug after reaching a target.

Trials measure body weight and HbA1c. This effect is reported consistently and is not a primary endpoint anywhere, so it rests on participant report rather than on measurement.

What the evidence actually supports#

This is the rare page on this site where the honest answer is that the evidence is genuinely strong.

• Species and route. Human, at the route people use, across tens of thousands of participants in randomised placebo-controlled trials published in full.
• Concentration of sources. Novo Nordisk sponsored the pivotal work. Unlike most of this site's subjects, that work has now been followed by a decade of independent prescribing data and post-marketing surveillance, which is a meaningfully different position from a drug resting on its sponsor's trials alone.
• Human data. STEP for weight, SUSTAIN for diabetes, SELECT for cardiovascular outcomes. The last of these is the one that matters most, because it counted events rather than measuring a surrogate.
• What has not been looked at. Use over decades, because the drug has not existed that long. And the average conceals a wide spread: some people lose a quarter of their body weight and some lose almost nothing, with no reliable way to know in advance which group someone is in.

Side effects and safety profile#

Nausea is the common complaint, worst in the first weeks and in the days after each dose increase, alongside diarrhoea, constipation and reflux. For most people it settles. The dose schedule steps up slowly for exactly this reason.

Two matters are not tolerability questions.

The label also advises against use for anyone with a personal or family history of medullary thyroid carcinoma or MEN2. The signal comes from rodent tumours that have not been shown to translate to humans, and it stays on the label regardless.

The lean tissue point deserves its own mention. Rapid weight loss takes muscle along with fat, and body composition data indicates a meaningful share of the total is not fat. Protein intake and resistance training are the available levers, and this matters more with age.

How it is dosed and administered#

Semaglutide is licensed, and its label was written from the trial data. That makes this section short and more reliable than anything reported second-hand.

The licensed products are once-weekly pen injections into the stomach, thigh or upper arm, plus a daily tablet for diabetes. Doses start low and step up at roughly four-week intervals. That is a tolerance schedule, not a delay.

The tablet is worth a separate note: it is poorly absorbed by design and carries specific instructions about timing relative to food and other medicines. Taking it casually is the main way people get nothing from it.

Escalation and stopping are decisions for the prescriber who knows the person's history.

Semaglutide compared with tirzepatide and liraglutide#

Against tirzepatide#

Tirzepatide acts on two receptors rather than one and beat semaglutide directly in SURPASS-2 on both weight and blood sugar. That is a head-to-head trial, which is a stronger form of evidence than comparing two separate programmes.

Semaglutide's counterweight is SELECT. It has the completed cardiovascular outcomes trial and tirzepatide does not, which is why many prescribers still reach for it first when the person in front of them already has heart disease.

Against liraglutide#

Liraglutide is the same family, cleared from the body faster, injected daily rather than weekly, and produces roughly half the weight loss. It stays in use mainly on cost, availability and its licence in younger patients.

Against retatrutide#

Retatrutide reported up to 28.3% mean weight loss in phase 3, against semaglutide's 15%. It is not approved anywhere and has no cardiovascular outcomes data. On weight the gap is large; on what has actually been proven, it runs the other way.

Frequently asked questions#

How quickly does it work?

Appetite usually changes within the first week or two, well before the scale does. Weight loss in the STEP trials continued for more than a year before flattening.

What happens if I stop?

Trials that withdrew it saw most of the weight return within a year. Appetite regulation reverts to how it was. That is a fact about the medicine rather than a failure of willpower, and it is why it is described as a long-term treatment rather than a course.

Is it safe to use for years?

The diabetes record now runs close to a decade and the safety profile has held. Nobody has data on thirty years of use, because the drug has not existed for thirty years.

Is Ozempic the same as Wegovy?

The same molecule at different doses under different licences. The long-running argument about "Ozempic for weight loss" is an argument about supply and licensing rather than about two different drugs.

Does it damage the thyroid?

A rare tumour seen in rodents has not translated into a demonstrated human risk. It remains on the label and rules out use for people with the specific inherited conditions named there.

Key takeaways#

• Semaglutide is a GLP-1 receptor agonist licensed for type 2 diabetes and weight management, given weekly by injection or daily as a tablet.
• The STEP trials reported roughly 15% mean body weight loss over 68 weeks against about 2.4% on placebo.
• SELECT found around 20% fewer major cardiovascular events in people with existing heart disease. That is the strongest evidence any compound covered on this site carries, because it counted events rather than a surrogate.
• Sustained severe abdominal pain warrants same-day medical attention, and the label advises against use with a personal or family history of medullary thyroid carcinoma or MEN2.
• Weight returns after stopping in the trials that tested it. The average also hides a wide spread, and nobody can predict who responds.

References#

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 2021. The STEP 1 trial.
2. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine, 2023. The SELECT trial.
3. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 2021.
4. The compound page on this site: semaglutide.